Skip to content

Efficacy Study of Stenting, Paclitaxel Eluting Balloon or Atherectomy to Treat Peripheral Artery Disease

Randomized Trial of Stenting After Dilation With or Without Paclitaxel Eluting Balloon or Atherectomy in Patients With Symptomatic Peripheral Artery Disease

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00986752
Acronym
ISAR-STATH
Enrollment
150
Registered
2009-09-30
Start date
2009-07-31
Completion date
2015-03-31
Last updated
2014-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral Vascular Diseases

Keywords

stent, atherectomy, paclitaxel-eluting balloon

Brief summary

The purpose of the study is to evaluate the efficacy of stenting after dilation with or without paclitaxel-eluting balloon or atherectomy in patients with symptomatic peripheral artery disease.

Detailed description

The superficial femoral artery is a common place for arteriosclerosis in patients symptomatic for lower extremity vascular disease. Advances in percutaneous transluminal angioplasty (PTA) and stenting have provided new options for the treatment of the disease in this arterial segment. Despite the initial technical success rate of more than 95% the late clinical failure remains an important concern. Restenosis after PTA occurs in 40-60% within one year. Percutaneous removal of the obstructive material through atherectomy may reduce restenosis rate. So far, data in support of excisional atherectomy derive from registries. Another attempt to reduce restenosis is the use of paclitaxel eluting balloons (PEB). First clinical studies suggest that the use of PEBs during percutaneous treatment of femoropopliteal disease is associated with significant reductions in late lumen loss and target-lesion revascularization. There is no randomized comparison of this three different interventional strategies. Thus the aim of this study is to evaluate the efficacy of these strategies in terms or reduction of diameter stenosis at follow-up angiogram.

Interventions

DEVICEStenting (Smart Stent)

Nitinol stent

DEVICEStenting after PEB (Smart Stent, Invatec)

Stenting (nitinol stent) after dilation with Paclitaxel-eluting balloon (PEB).

PROCEDUREAtherectomy (SilverHawk device)

Atherectomy

Sponsors

Deutsches Herzzentrum Muenchen
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Symptomatic ≥ 70% stenosis of the SFA (Rutherford stage 2-6) * Written informed consent

Exclusion criteria

* Acute ischemia and/or acute thrombosis of the SFA * Untreated ipsilateral iliac artery stenosis \>70% * Previous stenting of the SFA * Popliteal stenosis \>70% * Severe renal insufficiency

Design outcomes

Primary

MeasureTime frame
Percentage diameter stenosis6 months

Secondary

MeasureTime frame
Major adverse peripheral events (MAPE) defined as acute thrombosis of SFA or ipsilateral amputation or revascularization (PTA or bypass surgery)6 months
Time to onset of any of MAPE.3-24 months
All-cause mortality6 and 24 months
Percentage diameter stenosis in duplex ultrasound6 and 24 months
Change from baseline in functional status and health related quality of life (Walking Impairment Questionaire)3 and 6 months
Binary restenosis rate6 months

Countries

Germany

Contacts

Primary ContactKlaus Tiroch, MD
tiroch@dhm.mhn.de+49-89-1218
Backup ContactTarek Ibrahim, MD
ibrahim@dhm.mhn.de+49 89-1218

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 27, 2026